Point of Care Host-Pathogen Monitoring System

Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: D17PC00032
Agency Tracking Number: D162-002-0188
Amount: $149,503.39
Phase: Phase I
Program: SBIR
Solicitation Topic Code: SB162-002
Solicitation Number: 2016.2
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2016-11-18
Award End Date (Contract End Date): 2017-11-27
Small Business Information
5603 Arapahoe Avenue Suite 1, Boulder, CO, 80303
DUNS: 961776577
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Michael Lochhead
 Chief Technology Officer
 (303) 952-2810
 mike.lochhead@mbiodx.com
Business Contact
 Cynthia Moore
Phone: (303) 952-2863
Email: cindi.moore@mbiodx.com
Research Institution
N/A
Abstract
Septic shock is a significant worldwide health problem that affects millions, but is complicated to treat since many of the signs and symptoms are non-specific and common to other non-infectious sources of systemic shock. Patient care would be improved by a rapid test to monitor key biomarkers and determine whether antibiotic use is appropriate. We propose to deliver a quantitative, multiplexed biomarker assay panel on a portable, inexpensive, easy-to-use cartridge-and-reader platform, with results provided in 10 minutes. MBio has already demonstrated a quantitative, portable, multiplexed platform for sensitive detection of biomarkers in a point-of-care test. This technology will be transformative for monitoring host-pathogen interactions in near real time, and it would enable personalized therapeutic interventions during acute severe infection such as sepsis. MBios technical innovations are directed at simplicity of the user experience and producing rapid results while not compromising on performance. In a Phase I award, we will measure procalcitonin, C-reactive protein, and interleukin-6. In a Phase II award, this panel of biomarkers will be expanded to include a wide range of other relevant host response biomarkers such as cytokines, hemopexin, and PAMPs, and interferon gamma-induced protein-10.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government